<DOC>
	<DOCNO>NCT01461928</DOCNO>
	<brief_summary>This multicenter , randomize , open-label , parallel-group study evaluate efficacy safety subcutaneously administer rituximab comparison observation maintenance therapy participant relapse refractory indolent Non-Hodgkin 's lymphoma ( NHL ) . All participant receive induction therapy rituximab ( 375 milligram per square meter [ mg/m^2 ] intravenously [ IV ] Cycle 1 , 1400 mg subcutaneous [ SC ] every 3-4 week ) plus standard chemotherapy 6-8 month ; follow 24 month maintenance I period rituximab ( 1400 mg SC every 8 week ) . Participants complete therapy show partial complete response randomize receive either rituximab ( 1400 mg SC every 8 week ) observation treatment maintenance II period follow least 15 month . Anticipated time study treatment disease progression , unacceptable toxicity end study , whichever occur first .</brief_summary>
	<brief_title>A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only Participants With Relapsed Refractory Indolent Non-Hodgkin 's Lymphoma Who Had Responded Rituximab-based Immunochemotherapy Induction 2-year Maintenance With Subcutaneous Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Histologically confirm Cluster Differentiation 20positive ( CD20+ ) follicular NHL Grade 1 , 2 3a , CD20+ indolent NHL ( Waldenstr√∂m 's macroglobulinemia lymphoplasmacytic lymphoma , marginal zone lymphoma ) accord World Health Organization ( WHO ) classification system Participants must receive must relapse refractory , one line adequate therapy prior enrollment , include least one line consist immunotherapy and/or chemotherapy and/or radiotherapy Eastern Cooperative Oncology Group ( ECOG ) performance status less equal ( &lt; = ) 2 Transformation highgrade lymphoma Aggressive lymphoma ( example , mantle cell lymphoma [ MCL ] ) Presence history central nervous system ( CNS ) lymphomatous disease Other malignancy within 5 year prior enrollment , except curatively treat carcinoma situ cervix , squamous cell carcinoma skin basal cell skin cancer , cervical carcinoma Stage 1B less , breast cancer situ localize prostate cancer Stage T1c treat curative intent relapse metastasisfree least 2 year prior enrollment Inadequate hematological , hepatic renal function Known human immunodeficiency virus ( HIV ) infection Active and/or severe infection ( e.g . tuberculosis , sepsis opportunistic infection , active hepatitis B C ) Pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>